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Background: Coronary artery disease (CAD) is associated with verbal memory decline, although deterioration may
be mitigated in individuals undertaking exercise interventions. Ceramide sphingolipids, suggested to play a role in
pathological neurodegeneration, have been associated with the development and progression of CAD but their
relationship with cognitive response to exercise has not been assessed. In this study, concentrations of very long
chain ceramides (C22:0 and C24:0) were assessed as predictors of changes in verbal memory performance over
1 year in subjects with CAD undertaking cardiac rehabilitation (CR).
Methods: Verbal memory was measured using the California Verbal Learning Test 2nd Ed. (CVLT-II), from which Z-scores
were calculated based on age, gender and education matched norms. Baseline plasma C22:0 and C24:0 ceramide
concentrations were measured from fasting blood samples using high performance liquid chromatography coupled
electrospray ionization tandem mass spectrometry (LC/MS/MS). Repeated measures general linear models were used to
determine the association between baseline plasma ceramides and the change in verbal memory performance over
1 year of CR controlling for age and body mass index (BMI).
Results: In patients with CAD (n = 33, mean age = 62 ± 9 years, 84.8% male, years of education = 17 ± 3 years), higher
baseline plasma C22:0 (F1, 29 = 5.30, p = 0.03) and C24:0 (F1, 29 = 4.04, p = 0.05) concentrations significantly predicted less
improvement in verbal memory performance over 1 year of CR controlling for age and BMI.
Conclusions: Plasma ceramide concentrations should be further examined as potential predictors of cognitive
response to exercise and worse cognitive outcomes in patients with CAD.
Trial registration: NCT01625754
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Coronary artery disease (CAD) is a leading cause of
disability and is responsible for approximately 7.3 million
deaths worldwide [1]. An under-recognized symptom
of particular importance in this population is cognitive
impairment, with specific disruptions in multiple cognitive
domains [2,3]. In particular, subtle changes in verbal* Correspondence: Krista.Lanctot@sunnybrook.ca
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reproduction in any medium, provided the ormemory performance may be an important marker of
cognitive decline in CAD [3]. Cardiovascular risk factors
such as obesity, hypertension, and abnormal lipid metab-
olism have been associated with poorer verbal memory
performance [3] and an increased rate of verbal memory
decline [2]. For CAD patients, cognitive functioning is
a major determinant of quality of life [4] with verbal
memory function being especially predictive of mortality
[5], physical disability [6], progression to dementia [7] and
interference with secondary prevention [8].
Elevated plasma concentrations of the very long chain
ceramides C22:0 and C24:0 have been associated with
the development of CAD [9] and with greater verbalLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with mild cognitive impairment [10] and incident Alzhei-
mer’s disease in community dwelling elderly women [11].
While ceramides have emerged as promising clinical
biomarkers of cognitive decline [10-12], their association
with cognitive response to exercise has not been studied.
Exercise is increasingly recognized as a promising inter-
vention to not only improve cardiac outcomes [13] but
also to delay verbal memory decline [14,15]; however,
effects of fitness and cognitive response to exercise can
be heterogeneous [16] indicating a need to explore the
mechanisms that may hinder the cognitive benefits of
exercise. Proinflammatory [17] and pro-apoptotic [18]
properties of ceramide lipid species may impair neural
adaptation to exercise and induce neurodegenerative
processes [19]. The present study evaluated the rela-
tionship between plasma concentrations of C22:0 and
C24:0 and change in verbal memory performance in




The protocol, including acquisition of informed consent,
for this prospective study was approved by the Sunny-
brook Health Sciences Centre Research Ethics Board and
the University Health Network Research Ethics Board.
Patients with CAD were recruited from a CR program
as described previously [8] and followed for 1 year.
Briefly, the CR program at the Toronto Rehabilitation
Institute is comprised of both aerobic and resistance
exercise under the supervision of exercise and medical
specialists. Following assessment of peak oxygen uptake
(VO2peak), a measure of fitness, participants attended
exercise visits that included an aerobic walk or walk/
jog per week for 36 weeks and once per month for the
remaining 3 months of the year. Participants were also
expected to independently exercise 5 out of 7 days of
the week. Participants were followed over the standard
48-week CR protocol. Ceramide assays were performed
at baseline. Memory testing was performed at baseline
and at 1-year follow-up.
Subjects
Eligible subjects who provided written informed consent
were assessed for inclusion/exclusion criteria. All CR
subjects had evidence of CAD (previous hospitalization
for acute myocardial infarction, coronary angiographic
evidence of ≥ 50% blockage in one or more major
coronary artery or prior revascularization). All subjects
had dyslipidemia and were being treated with statins.
Subjects were excluded based on previously diagnosed
neurodegenerative illness including all-cause dementia,
active cancer, surgery planned within 12 months, schizo-phrenia, bipolar affective disorder, and substance abuse.
The Mini Mental Status Examination (MMSE) was used
to screen for dementia and subjects with MMSE < 24 [20]
were excluded.
Assessments
Verbal memory was assessed using the California Verbal
Learning Test 2nd Ed. (CVLT-II), which yields a sensitive
measure of long delay free recall (LDFR) of a word list
after 20 minutes in addition to measures of verbal learning
(recall of a word list over 5 learning trials) and short delay
free recall (recall of a word list after 10 minutes) [21].
A trained researcher administered the CVLT-II at a
standardized time (0930 hr ± 30 min). A Z-score was
computed from age, gender and education matched
norms. Z-scores follow a normal distribution with a
standard deviation of 1.0; higher Z-scores reflect better
performance.
Demographic and clinical characteristics, as well as a
detailed medical history including comorbidities inde-
pendent of CAD were collected from patient interviews.
Cardiac medical history, concomitant medications, cardiac
health indicators (body mass, height, hyperlipidemia, hyper-
tension, diabetes, waist circumference) and anthropomet-
rics were obtained from patient charts at the Toronto
Rehabilitation Institute. Body mass index (BMI) was
calculated per standard definition [mass (kg)/(height (m)2)].
Sphingolipid measurements
Fasting blood was drawn at 0900 h ± 30 min, on the
same day as the cognitive testing, centrifuged at 1000 g
for 10 min at 4°C. Plasma was immediately isolated and
stored at −80°C until analysis. Quantification of individual
ceramide species was accomplished by high performance
liquid chromatography coupled electrospray ionization
tandem mass spectrometry (LC/MS/MS) using multiple
reaction monitoring as previously described [22]. Ceramide
species were assessed as continuous variables in units of
counts per second (cps), a commonly used quantification
of area under the curve for multiple reaction monitoring
assays.
Statistical analysis
All analyses were performed using SPSS statistical soft-
ware (version 19.0; IBM, Armonk, NY) and considered
significant at a two-tailed p ≤ 0.05. Plasma ceramide mea-
surements were log-transformed and associations between
ceramide concentrations and baseline patient characteristics
were assessed by Pearson correlations or univariate analyses
of variance as appropriate. Repeated measures general linear
models were used to determine the association between
baseline plasma ceramide concentrations and the change
in CVLT-II Z-scores between baseline and follow-up visits.
Age and BMI were included as possible confounders
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literature [10,12]. Pearson correlations were used to
determine the direction of the associations using change
scores over 1 year calculated by subtracting the baseline
Z-scores from the follow-up Z-scores.
Results
Demographics and cardiac risk factors are reported in
Table 1 (n = 33). Mean age was associated with baseline
C24:0 (r = −0.38, p = 0.03) but not C22:0 (r = −0.24, p = 0.18)
concentrations. There were no other significant associa-
tions between baseline ceramide concentrations and
sociodemographic characteristics, cardiac risk factors,
CAD severity, medical comorbidities, cardiopulmonary
fitness parameters or concomitant medications used.
Median plasma C22:0 concentrations at baseline were
1.53 × 106 cps (interquartile range = 1.06 × 106 - 1.93 × 106)
and C24:0 concentrations were 7.81 × 106 (interquartile
range = 5.94 × 106 - 1.02 × 107). Mean LDFR Z-score
increased from 0.06 ± 1.01 at baseline to 0.94 ± 0.97 at
follow-up after 1 year. In repeated measures analyses
controlling for age and BMI, significant ceramides × time
interactions were found within subjects; higher baseline
log C22:0 (F1, 29 = 5.30, p = 0.03) and C24:0 (F1, 29 = 4.04,
p = 0.05) concentrations were significantly predictive of
less improvement in verbal memory performance. As
shown in Figure 1, subjects with high plasma C22:0 and
C24:0 concentrations (top 50%) had 34% and 37% less
improvement in verbal memory performance compared
to those with low plasma C22:0 and C24:0 concentrations
(bottom 50%) respectively. Between-subjects comparisons
showed no associations between LDFR Z-scores and
baseline concentrations of C22:0 (F1, 29 = 1.18, p = 0.29)
or C24:0 (F1, 29 = 0.27, p = 0.61).
The associations between C22:0 (F1, 29 = 4.67, p = 0.04)
and C24:0 (F1, 29 = 4.91, p = 0.04) and less improvement in
LDFR scores remained significant in a post-hoc repeated
measures model controlling for baseline VO2peak and age.
Discussion
This is the first study to assess the relationship between
very long chain ceramide species measured in the blood
and memory performance in patients with CAD. This
study demonstrates an association between higher baseline
plasma ceramide concentrations and less improvement
in verbal memory performance in patients with CAD
participating in CR. We observed an inverse correlation
between plasma ceramide concentrations and age among
individuals with CAD, which is in line with Gorska et al.
[23]. However, many other studies, mostly in animal
models, suggest that ceramides increase with age (please
see review of Cutler & Mattson [24]). The relationships of
ceramides to age are complex and appear to depend on
the species of ceramide and site of sampling (peripheralversus brain versus cerebrospinal fluid). As such, the exact
relationships between age and ceramide concentrations
remain to be determined. Epidemiological studies with
large sample sizes examining ceramide levels in the
population, and factors that affect them (e.g., gender,
disease states) will be needed to address this question.
Baseline concentrations of plasma ceramides in this
study were similar to other reports that have used LC/
MS/MS with quantitative measures of analyte area [12,25].
Baseline participant memory scores were in the non-
impaired range and consistent with other studies assessing
memory impairment in healthy elderly [12] and those
with CAD [8,26]; however, even subtle deficits in verbal
memory performance are associated with poorer clinical
outcomes in patients with CAD [8].
Overall, participants experienced an improvement in
verbal memory performance over the course of the 1-year
CR program, which is consistent with a large body of
evidence showing improvements in cognitive performance
due to physical exercise in the elderly [15,27]. However,
patients with higher baseline plasma C22:0 and C24:0
concentrations showed less improvement when controlling
for age and BMI compared to those with lower baseline
plasma ceramide concentrations. The magnitude of the
estimate suggests that a 1 standard deviation higher base-
line C22:0 concentration predicted less improvement
on the CVLT-II by approximately 1–2 words, which is
equivalent to at least 8 years of cognitive aging.
These findings are consistent with previous findings in
98 elderly community dwelling women where higher con-
centrations of serum very long chain ceramides including
C24:0 were significantly associated with an increased risk
of incident verbal memory impairment and Alzheimer’s
disease over 9 years [11,12]. Similar trends were observed
between higher baseline plasma concentrations (C22:0
and C24:0) and decline in verbal memory performance on
the CVLT in a prospective study of subjects with mild
cognitive impairment. In that study, higher plasma con-
centrations of C22:0 and C24:0 at baseline also predicted
hippocampal volume loss over 1 year [10]. Consistent with
the between-subjects findings in the present study, no
cross-sectional relationships between plasma ceramides
and verbal memory test scores were identified in those
studies. Taken together, these findings suggest that high
ceramide levels in the blood may be relevant to memory
changes over time in patients with CAD despite exercise.
While neural adaptations to exercise are incompletely
understood, they are associated with markers of neuro-
genesis and angiogenesis in patients with CAD [28]. This
may be particularly relevant in the hippocampus [29]
since physical activity can reverse loss of hippocampal
volume, a correlate of memory performance, associated
with aging [14]. It could be hypothesized that ceramide
mediated formation of reactive oxygen and nitrogen
Table 1 Demographics and clinical characteristics of subjects (n = 33) and associations with C22:0 and
C24:0 concentrations
CAD (n = 33)










Age (yrs) 62 ± 9 r = −0.24 0.18 r = −0.38 0.03*
Sex (% male) 84.8 (28) F = 0.16 0.69 F = 0.12 0.74
Ethnicity (% Caucasian) 90.9 (30) F = 0.81 0.38 F = 0.28 0.60
Marital status (% married) 75.8 (25) F = 2.56 0.12 F = 2.00 0.17
Employed (% employed) 48.5 (16) F = 0.03 0.86 F = 0.07 0.79
Years of education (yrs) 17 ± 3 r = −0.01 0.97 0.09 0.62
Body composition
Body mass index (kg/m2) 28.2 ± 3.6 r = 0.27 0.13 r = 0.27 0.13
Body fat (%) 28.3 ± 7.4 r = 0.24 0.19 r = 0.19 0.29
Body mass (pounds) 185.1 ± 27.3 r = 0.22 0.22 r = 0.27 0.13
Waist circumference (cm) 99.6 ± 9.7 r = 0.08 0.68 r = 0.08 0.67
CAD severity
Cumulative stenosis (%) 132.9 ± 45.9 r = 0.05 0.78 r = 0.06 0.73
Number of vessels stenosed 2 ± 1 r = 0.02 0.92 r = 0.11 0.54
Time since acute coronary event (wks) 28.7 ± 76.7 r = 0.09 0.61 r = 0.11 0.53
Cardiac history % (n)
Myocardial infarction 54.5 (18) F = 1.38 0.25 F = 3.40 0.08
Coronary artery bypass graft surgery 39.4 (13) F = 0.97 0.33 F = 1.79 0.19
Stent 57.6 (19) F = 1.20 0.28 F = 3.94 0.06
Angina 27.3 (9) F = 0.55 0.46 F = 0.89 0.35
Hypertension 57.6 (19) F = 0.65 0.43 F = 0.30 0.59
Comorbidities % (n)
Diabetes 15.2 (5) F = 0.85 0.37 F = 1.09 0.30
Depression 36.4 (12) F = 1.48 0.23 F = 1.19 0.28
Hypercholesterolemia 100 (33) - - - -
Cardiopulmonary fitness parameters
Maximum heart rate (bpm) 124.3 ± 19.6 r = 0.13 0.46 r = 0.18 0.33
Maximum systolic blood pressure (mm Hg) 181.6 ± 28.3 r = 0.15 0.40 r = 0.06 0.73
Maximum diastolic blood pressure (mm Hg) 82.4 ± 11.6 r = −0.004 0.98 r = 0.01 0.94
VO2 peak (ml/kg/min) 20.7 ± 5.3 r = −0.13 0.49 r = −0.10 0.60
Medications % (n)
B-blocker 81.8 (27) F = 0.17 0.68 F = 0.01 0.93
Diuretic 21.2 (7) F = 0.90 0.35 F = 0.15 0.70
Anti-hypertensive 57.6 (19) F = 0.67 0.42 F = 0.13 0.72
Ca2+ channel blocker 12.1 (4) F = 0.11 0.74 F = 0.35 0.56
Antidiabetic 9.1 (3) F = 0.65 0.43 F = 0.25 0.62
Statin 100 (33) - - - -
Anxiolytic 6.1 (2) F = 0.84 0.37 F = 0.69 0.41
Antidepressant 6.1 (2) F = 0.30 0.59 F = 0.41 0.53
*two-tailed significance in one-way ANOVA or Pearson correlations.





















Percent improvement in verbal memory performance 
over 1 year of cardiac rehabilitation (CR) in subjects 
with low and high C22:0 and C24:0 concentrations  
Low 
High 
Figure 1 Percent improvement in verbal memory performance
over CR in low (bottom 50%) and high (top 50%) ceramide
groups. In a repeated measures model, significant within subjects
effects (F1,29 = 5.30, p = 0.03; left panel) indicated less improvement in
verbal memory performance over 1 year in subjects with high C22:0
concentrations (red) compared those with low C22:0 concentrations
(blue). Less improvement in verbal memory performance over 1 year
(F1,29 = 4.04, p = 0.05; right panel) was also found in subjects with high
C24:0 concentrations (red) compared to those with low C24:0
concentrations (blue). No significant between-subjects effects
were found.
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may interfere with neural adaptation to exercise and the
suggested involvement of ceramides in apoptotic cascades
leading to brain cell death [30] may contribute to neu-
rodegeneration underlying cognitive decline. In addition,
ceramide transporting proteins (CERTs) have been recently
identified in the blood and shown to interact with proteins
associated with dementia pathology such as serum amyloid
P component [31,32]. Thus, a variety of mechanisms may
relate ceramide concentrations to cognitive decline.
The present findings may also offer preliminary indica-
tions of potential therapeutic interventions. Both C22:0
and C24:0 are synthesized by ceramide synthase 2, which
has a sphingosine-1-phosphate (S1P) receptor like motif
and can be competitively inhibited by fingolimod (fTY720),
a first-in-class S1P analogue targeting 4 of the 5 S1P
receptor subtypes. Fingolimod has been recently approved
by the American Food and Drug Administration for the
treatment of multiple sclerosis [33]. Its role in modulating
ceramide synthesis and signaling [34] provides proof of
concept that ceramide synthesis is a possible drug target.
Specifically, inhibiting ceramide synthase 2 may be useful
in modulating ceramide synthesis and signaling [34] in
CAD patients who show aberrant ceramide metabolism
and verbal memory decline. Recently, aerobic exercise was
shown to decrease ceramides in the skeletal muscle of
obese individuals [35] suggesting that future studies in this
population would provide a unique opportunity to assess
exercise as an effective intervention for the modulation
of aberrant sphingolipid metabolism and preservation
of cognitive performance.This pilot study was limited by a small sample size,
which reduced the number of potential confounders that
could be controlled for; however, the associations found
were robust to adjustment with age, BMI and VO2peak.
Also, the change in plasma ceramide concentrations was
not assessed but changes in ceramide concentrations
might have offered further insight into whether exercise
can modulate ceramide concentrations. Practice effects
may have contributed to the overall improvement in verbal
memory; however, a one-year interval between testing
would be expected to minimize such effects on tests of
verbal memory [36]. While the results of this study
may not be generalizable to all patients with CAD
undergoing CR, the sample characteristics are similar
to a much larger group of CAD patients undergoing
CR described previously [37]. Potential referral bias and
patients undertaking different exercise regimes might
further limit the generalizability of the results. Future
prospective longitudinal studies with adequate power
are needed to explore the association between plasma
ceramides and memory performance and change in VO2peak
in subjects with CAD. In addition, the sensitivity and
specificity of C22:0 and C24:0 as possible plasma bio-
markers of cognitive response in CAD should be assessed
in future studies; however, C22:0 and C24:0 may be
particularly important as they have been prospectively
associated with dementia [11].
Conclusions
Baseline C22:0 and C24:0 concentrations were significantly
associated with change in verbal memory performance over
1 year of CR with higher ceramide concentrations predict-
ing less improvement. These preliminary findings suggest
that ceramides and other sphingolipid species should
be explored as prospective cognitive biomarkers in patients
with CAD. Future studies are needed to clarify the as-
sociation between sphingolipid metabolism and cognitive
changes in this and other populations.
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